[{"NetIncomeLossConverted_3_Q3_USD":-181651000.0,"NetIncomeLossConverted_1_Q3_USD":-66197000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-105118000.0,"CommonStockSharesOutstanding_0_Q3_shares":139755839.0,"StockholdersEquity_0_Q3_USD":1118731000.0,"EarningsPerShareBasic_1_Q3_USD":-0.52,"EarningsPerShareBasic_3_Q3_USD":-1.55,"Assets_0_Q3_USD":1222500000.0,"CommonStockSharesConverted_0_Q3_shares":139755839.0,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20201104"}]